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Abstract. Background: CAR-T cell therapy is likely to be introduced starting from 2021 in patients 
with relapsed/refractory myeloma (r/r MM) in Europe. In order to qualify for commercial CAR-
T treatment, it is assumed that r/r MM patients will have to be exposed to at least three lines of 
previous treatments including lenalidomide, bortezomib and anti-CD38 treatment. However, the 
outcome of this particular subgroup of r/r MM patients is largely unknown whereas this 
knowledge is crucial to estimate the possible benefit of eventual CAR-T treatment. 
Methods: In this non-interventional, retrospective single-center study, we analyzed all subsequent 
r/r MM patients treated between 01/2016 (when anti-CD38 treatment was commercially 
introduced in Switzerland) and 04/2020 at the University Hospital of Bern. Patients were eligible 
for the study if they had received at least three lines of treatment including one proteasome 
inhibitor (PI), one immunomodulatory drug (IMID) and one anti-CD38 antibody, and if they were 
in need of subsequent treatment and effectively received further lines of treatment.  
Results: Among 56 patients fulfilling the criteria of at least three lines of treatment including PI, 
IMID and anti-CD38 treatment, only 34 (60%) effectively received subsequent further therapy. 
This suggests that 40% of r/r MM patients never receive additional treatment after at least three 
lines of treatment including PI, IMID and anti-CD38 treatment. For patients receiving further 
treatment, the median number of previous lines of treatment was 4.5 (range 2-12), including 
autologous stem cell transplantation in 31 (91%) patients. 13 (37%) patients were penta-refractory. 
The most frequently used treatment options were IMID/dexamethasone treatment in 11 (32%) 
patients, followed by PI/dexamethasone in 10 (29%) patients. 21 (62%) patients received two or 
more additional lines of therapy. The median PFS was 6.6 months (range 0–36.6 months), the 
median TTNT was 7.5 months (range 1.4-24.5 months) and the median OS was 13.5 months, (range 
0.1-38 months) for the first subsequent treatment. The overall response rate (ORR) to the first 
subsequent treatment was 41%, with a median duration of the response of 5 months (range 1-37 
months). 12% of the patients achieved VGPR or better, with a median duration of response of 8 
months (range 3-37 months).  
Conclusions: Myeloma patients refractory after at least three lines of anti-CD38/PI/IMID 
treatment have a poor prognosis with a PFS of 6.6 months and OS of 13.5 months. These data may 
serve as reference to compare the potential benefit of CAR-T treatment in this group of myeloma 
patients when available in the near future. 
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Introduction. Due to demographic changes, the 
incidence of multiple myeloma (MM) is increasing, and 
2% of all cancer-related mortalities are caused by 
MM.1,2 The introduction of novel therapeutic 
compounds including proteasome inhibitors (PI, e.g. 
bortezomib, carfilzomib, and ixazomib), 
immunomodulatory drugs (IMiD, thalidomide, 
lenalidomide, and pomalidomide) and monoclonal 
antibodies (e.g. daratumumab and isatuximab, targeting 
CD38) have prolonged survival of patients with MM. 
Therefore, prevalence of multiple myeloma has been 
significantly increasing.3-8 However, almost all 
myeloma patients will ultimately relapse at some stage, 
and the disease remains incurable.7-11 This emphasizes 
the unmet need for new and more effective therapeutic 
modalities. Inhibition of exportin1 by selinexor,12,13,14 
protease inhibition by nelfinavir,15,16 and anti-SLAMF7 
activity by elotuzumab17 represent recent approaches. 
Since 2019, therapy with genetically modified T-
cells expressing a chimeric antibody receptor (CAR-T) 
was commercially introduced for the treatment of 
relapsed/refractory (r/r) aggressive B-cell lymphomas 
and acute lymphoblastic B-cell leukemia in Switzerland. 
Currently, CAR-T cell therapy is further evaluated for 
patients with r/r MM in clinical studies and will soon be 
in commercial use.3,6,9,18-33 The majority of the clinical 
CAR-T cell trials in multiple myeloma target the B-cell 
maturation antigen (BCMA), which shows predominant 
expression on myeloma and normal plasma cells, in 
contrast to low or absent expression on other cell 
compartments.6,34-36 
As CAR-T therapy will soon be introduced for 
commercial treatment of r/r MM patients, it is of utmost 
interest to learn the possible benefit of this novel 
therapeutic option for this subset of myeloma patients. 
As a basis, knowledge of the outcome of such r/r MM 
patients in the pre-CAR-T era is crucial. In the present 
study, we, therefore, aimed at characterizing this group 
of r/r MM patients as a basis for later comparisons with 
CAR-T treated MM patients. CAR-T in MM will most 
likely be restricted to patients with at least three previous 
lines of treatment with at least one PI, one IMID and one 
anti-CD38 antibody. Consequently, this study intends to 
describe the outcome of MM patients effectively 
receiving further treatment for progressive disease after 
three lines of treatment including at least one PI, one 
IMID and one anti-CD38 antibody. 
 
Methods. 
Patients. This non-interventional, single-center, 
retrospective study analyzed patients with r/r MM 
diagnosed between 01/2016 (when anti-CD38 treatment 
was commercially introduced in Switzerland) and 
04/2020 at the University Hospital of Bern, Switzerland. 
Patients were eligible for the study, if they had received 
at least one proteasome inhibitor, one 
immunomodulatory drug and an anti-CD38 antibody, as 
well as a total of at least three lines of treatment. The 
study was approved by a decision of the local ethics 
committee of Bern, Switzerland, and all participants 
have given written informed consent. 
 
Treatment. We summarized lenalidomide, thalidomide 
and pomalidomide as immunomodulatory drugs 
(IMiD’s). The group of proteasome inhibitors (PI) 
comprised carfilzomib, bortezomib and ixazomib. 
Alkylating agents (Alky) were melphalan, 
bendamustine, cyclophosphamide, vincristine, 
doxurubicin and etoposide. Antibody treatment 
comprised anti-CD38-antibodies (daratumumab; 
isatuximab) and anti-SlamF7 antibody (elotuzumab).  
 
Definitions. Progression-free survival (PFS) was 
calculated from the start of the first treatment after 
inclusion in the study until first progression of MM or 
death of any cause, whichever occurred first. 
Progression was defined as an increase of at least 25% 
in measurable monoclonal immunoglobulin in serum or 
urine or an increase of ≥25% in urinary light chains.37,38 
Overall response rate (ORR) was defined as the 
percentage of patients with at least partial response or 
better according to IMWG Uniform Response Criteria.10 
Time to next treatment (TTNT) was the time between 
start of the first treatment after inclusion in the study 
until the first day of the next treatment regimen. Overall 
survival (OS) was assessed from the start of the first 
treatment after inclusion in the study until death or last 
follow-up with a data cut-off at April 04, 2020, 
whichever occurred first. 
 
Statistical analysis. PFS, TTNT, and OS were calculated 
according to the Kaplan-Meier method and were 
depicted using Graphpad (Graphpad, Prism 8, Version 
8.2.1 (441), August 20, 2019). Statistical analyses were 




Patients. We identified 56 multiple myeloma (MM) 
patients, who had received at least one PI, one IMID and 
one anti-CD38 treatment, and a total of at least three 
lines of treatment, between 01/2016 and 04/2020 at the 
University Hospital Bern, Switzerland. Of these 56 
patients, 34 effectively received subsequent further  
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Table 1. Patient characteristics at first diagnosis of the multiple 
myeloma. 
 Parameter Results  
 Age at diagnosis, median (range) 63 (42-78) 
  <65 years, n (%) 20 (59%) 
  ≥65 years, n (%) 14 (41%) 
  <75 years, n (%) 33 (97%) 
  ≥75 years, n (%) 1 (3%) 
 Sex   
  males/females (ratio) 25/9 (2.8) 
 Paraprotein subtype, n (%)   
  IgG 16 (57%) 
  IgA 12 (43%) 
  kappa light chain 20 (63%) 
  lambda light chain 12 (38%) 
  light chain only, n (%) 5 (15%) 
 BM infiltration, median (range (%) 0,6 (20%-99%) 
 Hypercalcemia (>2.6 mmoL/L), n (%) 7 (21%) 
 Renal failure, n (%) 11 (32%) 
 Serum creatinine median, μmol/L (range) 85 (49-492) 
 Anemia (<100 g/L), n (%) 25 (74%) 
 Hemoglobin, median g/L (range) 101 (71-146) 
 Osteolytic lesion, n (%) 23 (68%) 
 ß2-microglobulin >3.5mg/L n (%) 19 (56%) 
 Albumin < 3.5 g/dL, n (%) 22 (65%) 
 LDH, >480 U/L 4 (12%) 
 Stage R-ISS   
  I, n (%) 10 (29%) 
  II, n (%) 6 (18%) 
  III, n (%) 18 (53%) 
 Cytogenetics   
  Available, n (%) 21 (62%) 
  
At least 1 high-risk aberration, n (% of 
known) 
6 (29%) 
IgG/IgA/IgM: Immunoglobulin type G, A, M; BM: bone marrow; 
LDH: Lactate dehydrogenase; R-ISS: Revised International Staging 
System; High risk aberration: t(4;14), t(14;16), t(14;20), del(17/17p), 
gain(1q), del(13). 
 
treatment, and these 34 patients were representing the 
cohort (100%) analyzed in this study. The patient 
characteristics at first diagnosis of these MM patients 
are summarized in Table 1. The median age at diagnosis 
was 62 years (range 35-78). A total of 27 (66%) patients 
had R-ISS disease stage of II or III; and 8 (24%) patients 
had at least one high-risk aberration including the gain 
of 1q, deletion 17p, or translocation t(4;14), t(6;14), or 
t(14;20).  
 
Prior therapies including daratumumab. Among the 34 
patients fulfilling the criteria of three treatment lines, 
including PI, IMID, and anti-CD38 treatment, and 
effectively receiving subsequent therapy line(s), the 
Table 2. Treatments prior and including first daratumumab 
treatment. 
 Parameter Results  
 Lines of prior therapy including daratumumab  
  2-3, n (%) 15 (44%)   
  4-5, n (%) 5 (15%)   
  6-7, n (%) 9 (26%)   
  8-9, n (%) 3 (9%)   
  >9, n (%) 2 (6%)   
 Prior therapy including daratumumab, n (%)  
  PI mono 19 (56%)   
  PI+Alky 26 (76%)   
  PI+IMiD 10 (29%)   
  IMiD mono 19 (56%)   
  IMiD+Alky 4 (12%)   
  Alky mono 4 (12%)   
  Anti-CD38 antibody mono 16 (47%)   
  Anti-CD38 antibody+PI 7 (21%)   
  Anti-CD38 antibody+IMiD 11 (32%)   
  Anti-SLAMF7 antibody+IMiD 1 (3%)   
  Anti-SLAMF7 antibody+PI+IMiD 1 (3%)   
  HDCT/ASCT 31 (91%)   
  Maintenance post HDCT/ASCT 21 (62%)   
#: Numbers of; PI mono: Proteasome inhibitor; PI + Alky: 
Proteasome inhibitor and alkylating agent; PI + IMiD: Proteasome 
inhibitor and immunomodulatory drug; IMiD mono: 
Immunomodulatory drug; IMiD + Alky: Immunomodulatory drug 
and alkylating agent; Alky mono: Alkylating agent; Anti-CD38 
antibody mono: Daratumumab; Anti-CD38 antibody + PI: 
Daratumumab and proteasome inhibitor; Anti-CD38 antibody + 
IMiD: Daratumumab and immunomodulatory drug; Anti-CD38 
antibody + IMiD + Alky: Daratumumab and immunomodulatory 
drug and alkylating agent; Anti-SLAMF7 antibody mono: 
Elotuzumab (Anti-SLAMF7 antibody); Anti-SLAMF7 antibody + PI 
+ IMiD: Elotuzumab and proteasome inhibitor and 
immunomodulatory drug; Dexa mono: Dexamethasone; 
HDCT/ASCT: High-dose chemotherapy and autologous stem cell 
transplantation. 
 
median number of previous lines was 4.5 (range 2-12 
lines). 24 (55%) patients had four or more prior therapy 
lines, mainly because anti-CD38 treatment was first 
given late in these patients. HDCT and ASCT were 
performed in 31 (91%) patients. The prior treatment 
lines are summarized in Table 2. 14 (40%) patients were 
quad-refractory, thus refractory to bortezomib, 
lenalidomide, carfilzomib, and pomalidomide, and 13 
(37%) patients were penta-refractory, thus refractory 
also to daratumumab.  
 
First treatment line after inclusion. The median interval 
from the initial diagnosis to the first treatment after 
fulfilling the study criteria was 67 months (range 19 to 
189 months). 11 (32%) patients received one subsequent 
treatment line, 13 (38%) patients received two 
subsequent treatment lines, and 8 (24%) patients  
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Table 3. Treatments after first daratumumab treatment. 
 Parameter Results 
 Therapy after daratumumab, n (%)  
  PI mono 10 (29%)   
  PI+Alky 2 (6%)   
  PI+IMiD 6 (18%)   
  IMiD mono 11 (32%)   
  IMiD+Alky 5 (15%)   
  Alky mono 9 (26%)   
  Anti-CD38 antibody mono 5 (15%)   
  Anti-CD38 antibody+PI 6 (18%)   
  Anti-CD38 antibody+IMiD 3 (9%)   
  Anti-CD38 antibody+IMiD+Alky 1 (3%)   
  Anti-SLAMF7 antibody mono 1 (3%)   
  Anti-SLAMF7 antibody+IMiD 5 (15%)   
  HDCT/ASCT, n (%) 6 (18%)   
  Maintenance therapy after HDCT/ASCT 2 (6%)   
 #Pat, still on daratumumab at cutoff, n (%) 2 (6%)   
 #Pat, died before cutoff date, n (%) 18 (53%)   
 No of lines after daratumumab, n (%)     
  1 line 11 (32%)   
  2 lines 13 (38%)   
  3 lines 5 (15%)   
  4 lines 1 (3%)   
  5 lines 2 (6%)   
 Overall response rate, % 41%   
  95% Confidence interval ±3   
 VGPR (VGPR&CR), % 12%   
  95% Confidence interval ±9   
 Median duration of response, months 
(range) 6 (1.7-37)  
 Time from initial diagnosis until first 
treatment after Daratumumab, median 
months (range) 67 (19-189)  
 Follow up time, median months (range) 12 (0.2-38)  
#: Numbers of; PI mono: Proteasome inhibitor; PI + Alky: 
Proteasome inhibitor and alkylating agent; PI + IMiD: Proteasome 
inhibitor and immunomodulatory drug; IMiD mono: 
Immunomodulatory drug; IMiD + Alky: Immunomodulatory drug 
and alkylating agent; Alky mono: Alkylating agent; Anti-CD38 
antibody mono: Daratumumab (Anti-CD38 antibody); Anti-CD38 
antibody + PI: Daratumumab and proteasome inhibitor; Anti-CD38 
antibody + IMiD: Daratumumab and immunomodulatory drug; Anti-
CD38 antibody + IMiD + Alky: Daratumumab and 
immunomodulatory drug and alkylating agent; Anti-SLAMF7 
antibody mono: Elotuzumab (Anti-SLAMF7 antibody); Anti-
SLAMF7 antibody + IMiD: Elotuzumab and immunomodulatory 
drug; HDCT/ASCT: High Dose chemotherapy and autologous stem 
cell transplantation; Cutoff date: 04. February 2020; Overall 
response rate: Patient with partial, very good partial, and complete 
response to the first medication after first daratumumab treatment; 
VGPR: Very good partial response to the first medication after first 
daratumumab treatment; CR: Complete response to the first 
medication after first daratumumab treatment. 
 
received three or more lines of treatment (Table 3). The 
most frequent treatment line was IMID/dexamethasone 
in 11 (32%) patients, followed by PI/dexamethasone in 
10 (29%) patients, alkylating agents in 9 (26%) patients, 
daratumumab combined with a PI in 6 (18%) patients, 
and PI combined with IMID in 6 (18%) patients. Six 
(18%) patients received HDCT/ASCT during relapse 
treatment.  
The ORR to the first treatment after study inclusion 
was 41%, with a median duration of response of 5 
months (range 1 to 37 months). 12% of the patients had 
an excellent partial response or better, with a median 
duration of this response of 8 months (range 3 to 37 
months). So far, 33 (59%) patients have died, all due to 
disease progression. 
 
Outcome. The median PFS after the first treatment line 
after inclusion in the study was 6.6 months (range, 0 to 
36.6 months; Figure 1A). For the patients with two or 
more further treatment lines, the median PFS was 6.6 
months (range, 0 to 24.5 months) compared to median 
PFS of 5 months (range, 0.1 to 36.6 months) for those 
with only one further line. The median TTNT between 
the first and the second treatment line was 7.5 months 
(range 1.4-24.6 months) for the patients with effectively 
at least two further lines of treatment (Figure 1B). The 
median OS of the cohort was 13.5 months (range, 0.1 to 
38.0 months) after starting the first line of treatment 
within the study (Figure 1C). For patients with two or 
more further treatment lines, the OS was 15.6 months 
(range, 3.5 to 38) compared to 7.5 months (range, 0.1 to 
36.6 months) for the patients with only one further 
treatment line.  
 
Discussion. This study describes the clinical 
characteristics, treatment lines, and clinical outcomes of 
a heavily pretreated group of myeloma patients in 
Switzerland. The inclusion criteria were selected in 
order to mirror the criteria likely to be used candidates 
for subsequent CAR-T treatment in the near future. In 
particular, we included r/r MM patients who had 
previous therapy with at least three treatment lines, 
including PI, IMID, and anti-CD38 therapy.39-41 
The patients in our CAR-T candidate cohort had a 
median of five prior therapy lines, similar to pretreated 
myeloma patient cohorts described in the literature that 
had received a median of two to seven previous 
therapies.3,9,12,40,42-45 In particular, 40% of our patients 
were quad-refractory, and 37% were penta-refractory. 
These proportions were comparable to previous studies 
on similar patient cohorts.12,13 
Patients received a median of two further therapy 
lines. Following the start of the first treatment line in our 
study, we found a short median PFS of 6.6 months, 
highlighting the short duration of response in the 
advanced disease stages of r/r MM patients. Related 
studies on retreatment with IMiD’s and PI’s after anti-
CD38 treatment reported even shorter survival rates, 
with a median PFS of 4 months for patients receiving 
PI’s, and three months for IMID’s.46 In similar patient 
cohorts, the median PFS was 3.7 months for selinexor 
and 3.4 months for nelfinavir.12,16  
In contrast, CAR-T studies describe a median PFS 
between 7.7,3 7.947 and 11.89 months in patients with r/r 
MM. Therefore, there is a difference of 3 to 5 months of 
the median PFS compared to our findings in this heavily  
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Figure 1. Kaplan-Meyer curves depicting (A) progression free survival, (B) time to next treatment and (C) overall survival of myeloma patients 
for the first subsequent treatment line after inclusion in the study, thus, after at least three previous treatment lines. 
 
pretreated myeloma patient group. This difference 
emphasizes the anti-myeloma efficacy of CAR-T cell 
treatment compared to conventional therapies in r/r MM 
patients. 
Overall survival (OS) rates were reported between 
1.7 and 5.5 months in anti-CD38 refractory patients.45,48 
Selinexor and nelfinavir studies found OS rates of 9.313 
and 21.6 months,16 respectively. This suggests that the 
OS rate of 13.5 months in our cohort compares rather 
favorably to other series. The heavier pretreated patient 
group might explain the difference in the selinexor 
studies and the less heavily pretreated patient group in 
the nelfinavir studies, respectively, as well as in the 
higher proportion of quad- and penta- refractory patients 
in the post daratumumab studies by Pick et al. and 
Lakshmann et al. 45,48 
We identified a median TTNT of 7.5 months in our 
cohort. Lakshman et al reported a median TTNT of 5.7 
months in patients refractory to daratumumab and 
combination therapies similar to our results.48 In contrast, 
Driessen et al. described better TTNT (10 and 12 
months) in two patients treated with nelvinavir.15  
The overall response rate was 41% in this study; in 
others, the ORR was 21%13 and 25%12 in the selinexor 
studies, 33%15 and 55%16 in the nelfinavir studies 28.6%, 
52%, and 67% in three studies investigating retreatment 
after daratumumab.45,46 In contrast, the ORR was higher 
with 60%,47 81%,3 and 85%9 in three CAR-T cell studies.  
Similarly, the response duration was 4 months for 
nelfinavir,16 4.4 months12 and 5 months13 for selinexor. 
In contrast, CAR-T studies reported response duration 
between 7.9 and 13 months,47 with a dose-dependent 
duration of the responses, with a median duration of 
response of 10.9 months.9 
In our study, the median follow-up from the start of 
the first treatment was 12 months, comparable to 
previous myeloma studies, which reported median 
follow-ups between 5.5 and 36 months.9,16,45,47,48 The 
median interval from initial diagnosis until the first 
treatment in the study was 67 months (range 19 to 189 
months). This seems comparable to other reports with 
intervals between 45.6 and 79.2 months for similar 
 




Conclusions. This study describes an instead poorly 
reported group of MM patients, which had received at 
least three lines of treatment and must have had PI, 
IMID, and anti-CD38 treatment. In addition, the patients 
must have had further progression, and at least one line 
of subsequent treatment must have been given. This first 
line of subsequent treatment is most likely the situation 
in which CAR-T treatment will become available. Our 
study identified for this line of treatment with currently 
available, non-CAR-T treatment options a median PFS 
of 6.6 months, a median TTNT of 7.5 months, and the 
median OS was 13.5 months. These numbers may serve 
as a reference when benefits of CAR-T treatment in r/r 
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